EPRX:NASDAQ, Eupraxia Pharmaceuticals Inc.
EPRX stock overview
Eupraxia Pharmaceuticals Inc. (EPRX:NASDAQ) closed at $6.89 on November 6, 2026,
up 4.39% on the day.
The stock trades 26.1% below its 52-week high of $9.32
and 30.2% above its 52-week low of $5.29.
Over the past year, it gained 10.6%.
Eupraxia Pharmaceuticals Inc. is part of the Health Care sector.
Key figures
- Price
- $6.89
- Day change
- +4.39%
- Volume
- 583,894
- Average volume
- 661,785
- Market cap
- 455M+
- 52-week range
- $5.29 – $9.32
- 50-day average
- $7.56
- 200-day average
- $7.27
Price action over the past year
In 252 trading sessions since November 6, 2025, EPRX closed higher on 120 days (48%).
Its best day was January 8, 2026 (+19.14%) and its worst was October 1, 2026 (-13.96%).
The stock moved 10% or more in a single session 6 times.
Recent signals
EPRX news
-
Oct 22, 2026:
Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
-
Oct 15, 2026:
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
-
Oct 9, 2026:
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
-
Sep 30, 2026:
Eupraxia Says Resolve Trial Updated Data Suggest Annual Dosing Possible in EoE Patients
-
Sep 30, 2026:
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
-
Sep 12, 2026:
Eupraxia Pharma (EPRX): When Painful Swallowing Nearly Disappeared, Investors Took Notice
-
Sep 8, 2026:
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences
-
Aug 13, 2026:
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
About Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. Its lead product candidate, EP-104IAR, is in development for the treatment of pain due to osteoarthritis of the knee. In addition, it is developing a pipeline of earlier-stage long-acting formulations.
Similar stocks
Find more stocks like EPRX with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.